Flecainide—a class 1C Na+ channel blocker that also normalizes RyR2 activity—has shown potential in CPVT patients but also has a black box warning for patients with any kind of structural heart disease.6, 7. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.